Table 1.
Clinical and procedural characteristics.
| Age, years | 81 ± 5 |
| Gender, female | 35 (35%) |
| Arterial hypertension | 89 (89%) |
| Diabetes mellitus | 23 (23%) |
| Dyslipidemia | 71 (71%) |
| Coronary artery disease | 60 (60%) |
| Peripheral artery disease | 9 (9%) |
| Congestive heart failure | 13 (13%) |
| History of stroke/TIA | 10 (10%) |
| STS Score | 3.4 ± 2.1 |
| Atrial fibrillation | 28 (28%) |
| Paroxysmal | 16 (57%) |
| Time since atrial fibrillation diagnosis, months | 24 (3; 52) |
| Baseline treatment | |
| Antiplatelet therapy | 99 (99%) |
| Oral Anticoagulation | 32 (32%) |
| Beta-blockers | 55 (55%) |
| Calcium channel blockers (non-dihydropyridine type) | 2 (2%) |
| Amiodarone | 4 (4%) |
| Echocardiography | |
| LVEF, % | 59 ± 10 |
| Mean gradient, mmHg | 40 ± 14 |
| Peak aortic valve gradient, mmHg | 66 ± 22 |
| Aortic valve area, cm2 | 0.7 ± 0.3 |
| Indexed Aortic Valve Area, cm2/m2 | 0.2 ± 0.1 |
| Left atrial volume index, ml/m2 | 42 ± 14 |
| TAVI procedure performed | 98 (98%) |
| Access site (n, %) | |
| Right femoral artery | 88 (90%) |
| Left femoral artery | 10 (10%) |
| Type of valve (n, %) | |
| Self-expanding valves | 41 (42%) |
| Balloon-expandable valves | 52 (53%) |
| Mechanically-expandable valves | 5 (5%) |
Data are provided as mean ± standard deviation, as median with interquartile range (1st; 3rd) or frequencies with percentages. LVEF, left ventricular ejection fraction; STS, society of thoracic surgeons; TAVI, transcatheter aortic valve implantation; TIA, transient ischemic attack.